Estimating treatment effects from observational data: Dissonant and resonant notes from the SYMPHONY trials

JAMA

Volumn 287, Issue 23, 2002, Pages 3130-3132

  Michels, Karin B ^a,b   Braunwald, Eugene ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIBRAFIBAN; STATINE DERIVATIVE;

ANALYTIC METHOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; OBSERVATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0037134952     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.23.3130     Document Type: Editorial

References (19)

1. Early statin initiation and outcomes in patients with acute coronary syndromes
2. Executive summary of the third report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
3. Early statin treatment following acute myocardial infarction and 1-year survival
4. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
5. Beneficial effects of pravastatin (±/-colestyramine/niacin) initiated immediately after a coronary event (The randomized Lipid-Coronary Artery Disease [L-CAD] Study)
6. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study: A randomized controlled trial
7. The Sibrafiban vs Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
8. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes
9. A renaissance for measurement error
10. The central role of the propensity score in observational studies for causal effects
11. Constructing a control group using multivariate matched sampling incorporating the propensity score
12. Invited commentary: Propensity scores
13. Discussion of the paper by Bickel and Kwon
14. Using multivariate matched sampling and regression adjustment to control bias in observational studies
15. Randomization, statistics, and causal inference
16. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
17. The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of an early aggressive simvastatin therapy
18. Pravastatin or atorvastatin evaluation and infection therapy (PROVE IT) - TIMI 22 Trial: Rationale and design